Glecaprevir + pibrentasvir (ABT493 + ABT-530) for the treatment of Hepatitis C

Hopethe H Hubbard, Eric Lawitz

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Introduction: Glecaprevir (formerly ABT-493, pangenotypic NS3/4A protease inhibitor) and pibrentasvir (formerly ABT-530, pangenotypic NS5A inhibitor) are second generation direct acting antivirals (DAA) for the treatment of chronic Hepatitis C (HCV). It is a fixed dose ribavirin (RBV)-free regimen with activity against genotypes (GT) 1–6. In vitro the two antivirals have synergistic activity with a high barrier to resistance and potent activity against common polymorphisms. It is once daily oral dosing with minimal absorption, primary biliary excretion, and negligible renal excretion, making it safe for patients with renal impairment. This regimen is being reviewed because it is the first pangenotypic regimen suitable for those with renal impairment and prior DAA failure. Areas covered: The key phase 2 and 3 trials which investigated the efficacy and safety of glecaprevir/pibrentasvir are reviewed by methodology, primary end point, baseline demographic data, response rates, and adverse events. Literature search methodology involved reviewing key abstracts presented at the American Association for the Study of Liver Disease and European Association for the Study of Liver. Expert commentary: The advantages and limitations of glecaprevir/pibrentasvir will be reviewed in comparison to its competitor drug on the market.

Original languageEnglish (US)
Pages (from-to)1-9
Number of pages9
JournalExpert Review of Gastroenterology and Hepatology
DOIs
StateAccepted/In press - Dec 6 2017

Fingerprint

Hepatitis C
Antiviral Agents
Kidney
Ribavirin
Chronic Hepatitis C
Protease Inhibitors
Liver Diseases
Therapeutics
Genotype
Demography
Safety
Liver
Pharmaceutical Preparations

Keywords

  • Chronic Hepatitis C
  • direct acting antivirals
  • glecaprevir/pibrentasvir
  • renal impairment sustained virologic response

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Glecaprevir + pibrentasvir (ABT493 + ABT-530) for the treatment of Hepatitis C. / Hubbard, Hopethe H; Lawitz, Eric.

In: Expert Review of Gastroenterology and Hepatology, 06.12.2017, p. 1-9.

Research output: Contribution to journalArticle

@article{10b1d449f73640fcb7cb267d39962719,
title = "Glecaprevir + pibrentasvir (ABT493 + ABT-530) for the treatment of Hepatitis C",
abstract = "Introduction: Glecaprevir (formerly ABT-493, pangenotypic NS3/4A protease inhibitor) and pibrentasvir (formerly ABT-530, pangenotypic NS5A inhibitor) are second generation direct acting antivirals (DAA) for the treatment of chronic Hepatitis C (HCV). It is a fixed dose ribavirin (RBV)-free regimen with activity against genotypes (GT) 1–6. In vitro the two antivirals have synergistic activity with a high barrier to resistance and potent activity against common polymorphisms. It is once daily oral dosing with minimal absorption, primary biliary excretion, and negligible renal excretion, making it safe for patients with renal impairment. This regimen is being reviewed because it is the first pangenotypic regimen suitable for those with renal impairment and prior DAA failure. Areas covered: The key phase 2 and 3 trials which investigated the efficacy and safety of glecaprevir/pibrentasvir are reviewed by methodology, primary end point, baseline demographic data, response rates, and adverse events. Literature search methodology involved reviewing key abstracts presented at the American Association for the Study of Liver Disease and European Association for the Study of Liver. Expert commentary: The advantages and limitations of glecaprevir/pibrentasvir will be reviewed in comparison to its competitor drug on the market.",
keywords = "Chronic Hepatitis C, direct acting antivirals, glecaprevir/pibrentasvir, renal impairment sustained virologic response",
author = "Hubbard, {Hopethe H} and Eric Lawitz",
year = "2017",
month = "12",
day = "6",
doi = "10.1080/17474124.2018.1411802",
language = "English (US)",
pages = "1--9",
journal = "Expert Review of Gastroenterology and Hepatology",
issn = "1747-4124",
publisher = "Expert Reviews Ltd.",

}

TY - JOUR

T1 - Glecaprevir + pibrentasvir (ABT493 + ABT-530) for the treatment of Hepatitis C

AU - Hubbard, Hopethe H

AU - Lawitz, Eric

PY - 2017/12/6

Y1 - 2017/12/6

N2 - Introduction: Glecaprevir (formerly ABT-493, pangenotypic NS3/4A protease inhibitor) and pibrentasvir (formerly ABT-530, pangenotypic NS5A inhibitor) are second generation direct acting antivirals (DAA) for the treatment of chronic Hepatitis C (HCV). It is a fixed dose ribavirin (RBV)-free regimen with activity against genotypes (GT) 1–6. In vitro the two antivirals have synergistic activity with a high barrier to resistance and potent activity against common polymorphisms. It is once daily oral dosing with minimal absorption, primary biliary excretion, and negligible renal excretion, making it safe for patients with renal impairment. This regimen is being reviewed because it is the first pangenotypic regimen suitable for those with renal impairment and prior DAA failure. Areas covered: The key phase 2 and 3 trials which investigated the efficacy and safety of glecaprevir/pibrentasvir are reviewed by methodology, primary end point, baseline demographic data, response rates, and adverse events. Literature search methodology involved reviewing key abstracts presented at the American Association for the Study of Liver Disease and European Association for the Study of Liver. Expert commentary: The advantages and limitations of glecaprevir/pibrentasvir will be reviewed in comparison to its competitor drug on the market.

AB - Introduction: Glecaprevir (formerly ABT-493, pangenotypic NS3/4A protease inhibitor) and pibrentasvir (formerly ABT-530, pangenotypic NS5A inhibitor) are second generation direct acting antivirals (DAA) for the treatment of chronic Hepatitis C (HCV). It is a fixed dose ribavirin (RBV)-free regimen with activity against genotypes (GT) 1–6. In vitro the two antivirals have synergistic activity with a high barrier to resistance and potent activity against common polymorphisms. It is once daily oral dosing with minimal absorption, primary biliary excretion, and negligible renal excretion, making it safe for patients with renal impairment. This regimen is being reviewed because it is the first pangenotypic regimen suitable for those with renal impairment and prior DAA failure. Areas covered: The key phase 2 and 3 trials which investigated the efficacy and safety of glecaprevir/pibrentasvir are reviewed by methodology, primary end point, baseline demographic data, response rates, and adverse events. Literature search methodology involved reviewing key abstracts presented at the American Association for the Study of Liver Disease and European Association for the Study of Liver. Expert commentary: The advantages and limitations of glecaprevir/pibrentasvir will be reviewed in comparison to its competitor drug on the market.

KW - Chronic Hepatitis C

KW - direct acting antivirals

KW - glecaprevir/pibrentasvir

KW - renal impairment sustained virologic response

UR - http://www.scopus.com/inward/record.url?scp=85036628889&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85036628889&partnerID=8YFLogxK

U2 - 10.1080/17474124.2018.1411802

DO - 10.1080/17474124.2018.1411802

M3 - Article

C2 - 29187007

AN - SCOPUS:85036628889

SP - 1

EP - 9

JO - Expert Review of Gastroenterology and Hepatology

JF - Expert Review of Gastroenterology and Hepatology

SN - 1747-4124

ER -